Literature DB >> 10230460

Interaction of paclitaxel (Taxol) and irradiation. In-vitro differences between tumor and fibroblastic cells.

N Cordes1, L Plasswilm, R Sauer.   

Abstract

AIM: Optimal dose and schedule of paclitaxel in combined drug-irradiation treatment could not be determined for most of tumors yet. The aim of this study was to compare in vitro cytotoxicity and radiosensitizing abilities as a function of single paclitaxel (Taxol) exposure in tumor and fibroblastic cells using different drug incubation irradiation intervals. MATERIAL AND
METHOD: A lung-carcinoma (SK-LU-1), glioblastoma (U-138 MG) and rodent fibroblast cell line (HyB14FAF28) were used. The clonogenic assay was applied for survival investigation. alpha beta-values were calculated using the linear-quadratic model (log S = -alpha D - beta D2). Cytotoxicity of Taxol was examined at 0 to 50 microM. Combined Taxol-radiotherapy exposure was accomplished with 10 microM Taxol plus 10 Gy irradiation (RT) following after a 1-hour and 9-hour interval. For controls cells were exposed to Cremophor EL/ethanol (CEL/eth) and a phosphate buffered saline (PBS).
RESULTS: Single Taxol exposure (10 microM) resulted in 0.54/0.50/0.84 (3-hours incubation) and 0.094/0.48/0.82 (15-hours incubation) survival of SK-LU-1, U-138 MG and HyB14FAF28 cells, respectively. Taxol concentrations from 2 to 50 microM only had cytotoxic effect in tumor cells. Single dose RT (10 Gy) led to cell survival of 0.0006/0.006/0.03. The diluent CEL/eth also showed cytotoxic activity. Taxol plus RT led to cell survival of 0.00025/0.0014/0.042 (1 hour) and 0.0004/0.0019/0.04 (9 hours) without significant difference between chosen time intervals. alpha beta-values showed great variation lacking evidence for definite radiosensitization. alpha increase after Taxol and alpha decrease after CEL/eth exposure were detected.
CONCLUSIONS: The data presented demonstrate a potential beneficial effect, described as co-operation, by combining Taxol and RT in human tumor cells and rodent fibroblasts. High intrinsic alpha components of the tumor cells as well as CEL/eth's antagonizing actions could be likely to disturb and influence paclitaxel's abilities leading to radiosensitization.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10230460     DOI: 10.1007/bf02742360

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  30 in total

1.  The inactivation of Chinese hamster cells by x rays: synchronized and exponential cell populations.

Authors:  C J Gillespie; J D Chapman; A P Reuvers; D L Dugle
Journal:  Radiat Res       Date:  1975-11       Impact factor: 2.841

2.  Subadditive interaction of radiation and Taxol in vitro.

Authors:  M L Ingram; J L Redpath
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-03-15       Impact factor: 7.038

3.  Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity.

Authors:  G G Steel; M J Peckham
Journal:  Int J Radiat Oncol Biol Phys       Date:  1979-01       Impact factor: 7.038

4.  Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck.

Authors:  C E Leonard; D C Chan; T C Chou; R Kumar; P A Bunn
Journal:  Cancer Res       Date:  1996-11-15       Impact factor: 12.701

5.  Cytotoxicity and cell-cycle effects of paclitaxel when used as a single agent and in combination with ionizing radiation.

Authors:  N Gupta; L J Hu; D F Deen
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-03-01       Impact factor: 7.038

Review 6.  The taxanes: dosing and scheduling considerations.

Authors:  E K Rowinsky
Journal:  Oncology (Williston Park)       Date:  1997-03       Impact factor: 2.990

7.  Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype.

Authors:  L Webster; M Linsenmeyer; M Millward; C Morton; J Bishop; D Woodcock
Journal:  J Natl Cancer Inst       Date:  1993-10-20       Impact factor: 13.506

8.  Taxol: a novel radiation sensitizer.

Authors:  R B Tishler; P B Schiff; C R Geard; E J Hall
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

9.  Changes in radiation survival curve parameters in human tumor and rodent cells exposed to paclitaxel (Taxol).

Authors:  J Liebmann; J A Cook; J Fisher; D Teague; J B Mitchell
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-06-15       Impact factor: 7.038

10.  Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel.

Authors:  L Milas; N R Hunter; K A Mason; C G Milross; Y Saito; L J Peters
Journal:  Cancer Res       Date:  1995-08-15       Impact factor: 12.701

View more
  1 in total

1.  Interstitial docetaxel (taxotere), carmustine and combined interstitial therapy: a novel treatment for experimental malignant glioma.

Authors:  Prakash Sampath; Laurence D Rhines; Francesco DiMeco; Betty M Tyler; Michael C Park; Henry Brem
Journal:  J Neurooncol       Date:  2006-04-25       Impact factor: 4.130

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.